Poor trial design seems to have been responsible for a phase III failure, but the company has not suffered as a result.
Discontinuations and an unusual revelation about Tecentriq’s breast cancer data dominated the R&D part of the company’s third-quarter results call.
Krystal Biotech shares have surged 53% so far this week on gene therapy data in two patients, but rivals are waiting in the wings.
The Swiss group has succeeded with its internally developed diagnostics, but buying in innovation has served Becton Dickinson well.
An October curse returns to haunt Convatec, and this time it has spooked the CEO.
Abbott Laboratories has posted decent results for its transcatheter aortic valve, but all-important US pivotal data are in the offing.
After buying Avexis for $8.7bn to access a potentially transformative treatment for spinal muscular atrophy, data approaches from Novartis.
In the Rewind trial, whose readout is due by year-end, Trulicity needs to avert heart complications and show clean safety to keep up with other glucose-lowering drugs.
Forming partnerships with a number of players in diabetes technology is the key to growth, according to Ascensia Diabetes Care.
The UK company Midatech Pharma is giving up on speciality drugs to focus on cancer and rare diseases – and it has Novartis in its sights.
Voxeleron is, like Google’s related company Deepmind, using artificial intelligence to analyse ocular images. Unlike Deepmind, it is employing a targeted approach.